Last Updated : December 1, 2023
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Waldenström's Macroglobulinemia
Draft recommendations posted for stakeholder feedback: November 30, 2023
End of feedback period: December 14, 2023
Draft Recommendation
Therapeutic Area: Acute lymphoblastic leukemia (ALL)
Draft recommendations posted for stakeholder feedback: November 30, 2023
End of feedback period: December 14, 2023
Draft Recommendation
Therapeutic Area: Chronic immune thrombocytopenia (ITP)
Draft recommendations posted for stakeholder feedback: November 23, 2023
End of feedback period: December 7, 2023